NCT06149611View on ClinicalTrials.gov

Mass Balance Study of TQB3616

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2024

Conditions
Breast Cancer
Interventions
DRUG

[14C] TQB3616

TQB3616 is a new type of cyclin-dependent kinase (CDK) 4/6 inhibitor.

Trial Locations (1)

215006

The First Affiliated Hospital of Soochow University, Suzhou

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

NCT06149611 - Mass Balance Study of TQB3616 | Biotech Hunter | Biotech Hunter